TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...
Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance ...
The addition of lurbinectedin — a novel alkylating agent and transcription inhibitor — to first-line maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) improved survival ...
Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained. Tukysa (tucatinib) may represent a new patient-friendly ...
The FDA accepted Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer, granting priority review. Phase 3 IMforte trial showed Zepzelca plus Tecentriq improved ...
An FDA approval is setting a new benchmark for future treatment for first-line small cell lung cancer. The FDA has greenlighted Jazz Pharmaceuticals’ Zepzelca, used in combination with Roche’s ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA ® (tucatinib) as part of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results